Drugs / APS001F
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01562626 | Sep 2012 → May 2021 | cancer | Anaeropharma Science, Inc. | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APS001F | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01562626 ↗ |
| Modality | Other / unclassified | “APS001F is a recombinant Bifidobacterium longum (a live bacteria normally found in the digestive tract) that has been modified to produce an enzyme, cytosine deaminase (CD).” NCT01562626 ↗ |
| Route | Other | “APS001F infusion on Days 1,2,3 of each 28 day cycle.” NCT01562626 ↗ |